About the Authors
- Itziar Montalvo
-
Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain
- Alfonso Gutiérrez-Zotes
-
Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain
- Marta Creus
-
Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain
- Rosa Monseny
-
Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain
- Laura Ortega
-
Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain
- Joan Franch
-
Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain
- Stephen M. Lawrie
-
Affiliation Division of Psychiatry, Kennedy Tower, Royal Edinburgh Hospital, University of Edinburgh, Edinburgh, United Kingdom
- Rebecca M. Reynolds
-
Affiliation Endocrinology Unit, University/BHF Centre for Cardiovascular Sciences, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom
- Elisabet Vilella
-
Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain
- Javier Labad
-
* E-mail: labadj@peremata.com
Affiliation Early Psychosis Program and Research Department, Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain
Competing Interests
SML has received financial support from Pfizer (formerly Wyeth) in relation to imaging studies of people with schizophrenia and bipolar disorder. SML has done consultancy work for Roche Pharmaceuticals in connection with a possible new treatment for schizophrenia. SML has also received honoraria for lectures, chairing meetings, and consultancy work from Janssen in connection with brain imaging and therapeutic initiatives for psychosis. JL has received honoraria for lectures from Janssen. IM, AGZ, MC, LO, RM, JF, EV and RMR have no biomedical financial interests or potential conflicts of interest. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: JL AGZ RMR SML. Performed the experiments: IM MC JF LO RM. Analyzed the data: JL IM. Contributed reagents/materials/analysis tools: RMR EV. Wrote the paper: IM RMR EV JL.